Search

everythinglearnresearchcommunity

for

Search:↓

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.

Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Squaric acid dibutylester effectively treats alopecia areata.

Different causes of beard hair loss have various treatments, including medications, lifestyle changes, and procedures to stimulate hair growth.

Improving blood vessel health and controlling uric acid may help manage alopecia areata.

Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.

PRP shows promise for treating mild alopecia areata but needs more research for cicatricial alopecias.

Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.

SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.

Nivolumab can cause hair loss as a rare side effect.

New treatments focusing on immune pathways show promise for stubborn hair loss.

A gene variant increases the risk of a type of hair loss by affecting hair protein production.

DPCP is effective for treating severe alopecia areata, but relapse is common.

Topical sensitizers have mixed success in treating alopecia areata.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

Our microbiome may affect the development of the hair loss condition Alopecia Areata, but more research is needed to understand this relationship.

Human hair follicle cells can help regenerate hair and reduce inflammation, aiding in hair loss treatment.

Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.

The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.

Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.

T-cell patterns in skin help distinguish alopecia areata from androgenetic alopecia.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

IFN-γ production by CD4 T cells is crucial for causing alopecia areata.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Two siblings both had a rare case of alopecia areata at the same time.

Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.

The patient's hair loss is most likely due to diffuse alopecia areata.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.